Moderna-Merck mRNA Vaccine Linked to Lower Melanoma Recurrence Risk
A novel mRNA cancer vaccine developed by Moderna and Merck is showing significant promise in helping melanoma patients reduce the chances of their tumors returning after surgery. The custom-brewed vaccine, which targets unique tumor mutations, was found to lower the…
Fresno Visalia, CA, October 23, 2026 —
An mRNA cancer vaccine developed by Moderna and Merck was reported to lower the risk of melanoma returning after surgery when used alongside standard post-surgery treatment. The trend summary says the vaccine reduced recurrence risk by 42% and is attracting attention in the Fresno-Visalia area.
The vaccine is described as customized to target mutations unique to a patient’s tumor. The summary characterizes the findings as promising, but does not provide details about the research study, including the number of patients, how long they were followed, or where or when the results were reported.
The 42% figure is presented as a reduction in risk. The summary does not clarify whether that figure refers to a relative or absolute reduction, nor does it provide the recurrence rates for patients who received the vaccine and those who did not. It also does not identify the standard post-surgery treatment used in combination with the vaccine.
Information about the vaccine’s regulatory status, availability to patients, or next steps in its development was not included in the summary. As a result, the reported finding alone does not establish when, or whether, the vaccine may become available as a treatment option.
The trend summary identifies Moderna and Merck as the developers but does not name the researchers or provide a study citation. Further details about the trial and how the reported risk reduction was calculated were not provided.
Story summarized from the original created by KFSNWebmaster@email.disney.com(KFSN-TV Fresno) on abc30.com, see more information here.
